SEC Form 4 · accession 0000899243-18-025346
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Fabio Lopez
Other
Castilian Ltd.
10% Owner
Daniel Tafur
10% Owner
Equilibria Capital Management Ltd
10% Owner
Varibobi Financial Holdings Ltd
10% Owner
Period of report
Sep 24, 2018
Accepted (ET)
Sep 26, 2018 · 7:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 24, 2018 | J | 1,521,863 | $0.00 | D | 0 | D | |
| Common StockF4 | Sep 24, 2018 | J | 676,324 | $0.00 | D | 0 | D | |
| Common StockF6 | Sep 24, 2018 | J | 325,799 | $0.00 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund ("Sely S") distributed 1,521,863 shares to its partners on a pro rata basis, for no consideration.
- F2As a partner of Sely S, Fabio Lopez, received 19,524 of the shares distributed by Sely S.
- F3EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund ("Sely I") distributed 676,324 shares to its partners on a pro rata basis, for no consideration.
- F4As partners of Sely I, Daniel Tafur and Equilibria Capital Management received 13,871 and 107,619, respectively, of the shares distributed by Sely I.
- F5EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund ("Sely II") distributed 325,799 shares to its partners on a pro rata basis, for no consideration.
- F6As partners of Sely II, Fabio Lopez and Daniel Tafur received 6,325 and 2,372, respectively, of the shares distributed by Sely II.